Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

Core Insights - Barinthus Biotherapeutics plc reported its financial results for Q2 2025, focusing on advancements in its immunotherapy programs, particularly VTP-1000 for celiac disease [1][5][12]. Clinical Developments - The company is advancing its VTP-1000 immunotherapy, currently in the Phase 1 AVALON trial, with the last cohort of the single ascending dose (SAD) portion being screened and the multiple ascending dose (MAD) portion initiated [2][6][7]. - The SAD data readout is expected early in Q4 2025, while MAD data is anticipated in mid-2026 [6][7]. - The Phase 1 trial of VTP-850 for prostate cancer is complete, showing encouraging signs of immunogenicity [7]. Financial Highlights - As of June 30, 2025, the company had cash and cash equivalents of $87.8 million, down from $100.6 million as of March 31, 2025, primarily due to operating activities [8]. - Research and development expenses for Q2 2025 were $8.0 million, a slight decrease from $8.3 million in Q1 2025, attributed to reduced preclinical activity and workforce [8][9]. - General and administrative expenses increased to $15.4 million in Q2 2025 from $12.6 million in Q1 2025, mainly due to unrealized foreign exchange losses [13]. Net Loss - The net loss for Q2 2025 was $21.1 million, or $(0.52) per share, compared to a net loss of $19.7 million, or $(0.49) per share in Q1 2025 [13][19]. Corporate Updates - Barinthus Bio is actively seeking partners for its VTP-300 program in chronic hepatitis B and other viral vector-based assets [4].